SSA
KZR

Schonfeld Strategic Advisors’s Kezar Life Sciences KZR Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,440
Closed -$26.6K – 2236
2024
Q2 		$26.6K Buy
+4,440
New +$33.7K ﹤0.01% 1991
2023
Q3 		– Sell
-6,630
Closed -$162K – 2046
2023
Q2 		$162K Buy
6,630
+1,503
+29% +$39.1K ﹤0.01% 1623
2023
Q1 		$160K Sell
5,127
-3,753
-42% -$217K ﹤0.01% 1590
2022
Q4 		$625K Sell
8,880
-3,681
-29% -$273K 0.01% 1406
2022
Q3 		$1.08M Sell
12,561
-4,989
-28% -$485K 0.01% 1211
2022
Q2 		$1.45M Buy
17,550
+11,100
+172% +$979K 0.01% 855
2022
Q1 		$1.07M Buy
6,450
+1,930
+43% +$277K 0.01% 959
2021
Q4 		$756K Buy
+4,520
New +$510K 0.01% 1061

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Schonfeld Strategic Advisors's KZR Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Kezar Life Sciences (KZR) in Q3 2024, closing a stake of 4,440 shares — an estimated $26.6K sold.

Schonfeld Strategic Advisors first reported a position in KZR in Q4 2021 and held it in 8 quarters. The position peaked at $1.45M in Q2 2022. 59 funds tracked by Wall St. Rank hold KZR as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Kezar Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 4,440 Kezar Life Sciences shares in Q3 2024, an estimated $26.6K.
  • Schonfeld Strategic Advisors first reported a position in Kezar Life Sciences in Q4 2021 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's Kezar Life Sciences position peaked at $1.45M in Q2 2022.
  • 59 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.